Filing Flows

Filing Flows › Companies › CV Sciences › Cash flow

CV Sciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$13K in Q2 2026 · −$522K over twelve months

Operating cash flow$20K
Capital spending−$7K
Free cash flow+$13K
Cash conversion cycle181 days

Analysis

In Q2 2026, CV Sciences generated $20K of operating cash flow and spent $7K on capital projects, leaving free cash flow of $13K. That is $225K less than in Q2 2025 ($238K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$492K; the largest uses were operating cash flow ($492K), net borrowing (+) / repaid (−) ($161K), capital spending ($30K); besides operations, cash came from other financing ($63K); the cash balance fell by $620K.

Operating cash flow was $20K against net income of −$775K. The largest differences: stock-based pay +$148K, prepaid and other assets +$92K, payables +$85K.

Its cash conversion cycle was 181 days (receivables 11 + inventory 233 − payables 63).

Free cash flow

CV Sciences: free cash flow by quarterCV Sciences: free cash flow by quarter−$122KQ3 2024−$182KQ4 2024−$121KQ1 2025$238KQ2 2025−$270KQ3 2025−$363KQ4 2025$98KQ1 2026$13KQ2 2026
Operating cash flow less capital spending.
CV Sciences: operating cash flow against capital spendingCV Sciences: operating cash flow against capital spendingOperating cash flowCapital spending−$122K$0Q3 2024−$164K$18KQ4 2024−$81K$40KQ1 2025$287K$49KQ2 2025−$259K$11KQ3 2025−$354K$9KQ4 2025$101K$3KQ1 2026$20K$7KQ2 2026
Latest (Q2 2026): Operating cash flow $20K, Capital spending $7K.

Capital allocation, year by year

CV Sciences: where the cash came from (up) and went (down), by fiscal yearCV Sciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$7.5MFY2021: Net borrowing $192KFY2021: Shares issued $4.4MFY2021: Capital spending −$35K$4.6MFY2021FY2022: Operating cash flow −$1.9MFY2022: Net borrowing $664K$664KFY2022FY2023: Operating cash flow $2.3MFY2023: Net borrowing −$1.1MFY2023: Acquisitions −$156K$2.3MFY2023FY2024: Operating cash flow −$861KFY2024: Net borrowing −$241KFY2024: Capital spending −$18KFY2024: Acquisitions −$10KFY2024FY2025: Operating cash flow −$407KFY2025: Net borrowing −$173KFY2025: Capital spending −$109KFY2025
Over these 5 years operating cash flow totalled −$8.4M; the largest uses were operating cash flow ($10.6M) and net borrowing ($1.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$266K
Debt$1.6M
Net debt$1.4M
Due within a year$18K
Cash runway6 months

CV Sciences is burning cash: its operations consume cash, a free cash flow of −$522K a year at the current rate against $266K of cash and investments: a runway of about 6 months; $18K of debt also comes due within a year, which would need refinancing or new money before any new financing.

Where the cash came from and went

CV Sciences: sources (+) and uses (−) of cash, Q2 2026CV Sciences: sources (+) and uses (−) of cash, Q2 2026Net borrowing (+) / repaid (−)−$54KCash drawn (+) / kept (−)$43KOperating cash flow$20KCapital spending−$7KExchange rates−$2K
CV Sciences: sources (+) and uses (−) of cash, TTM to Q2 2026CV Sciences: sources (+) and uses (−) of cash, TTM to Q2 2026Cash drawn (+) / kept (−)$620KOperating cash flow−$492KNet borrowing (+) / repaid (−)−$161KOther financing$63KCapital spending−$30K

From profit to cash

CV Sciences: net income to operating cash flow, Q2 2026CV Sciences: net income to operating cash flow, Q2 2026Net income−$775KDepreciation & amortization$22KStock-based pay$148KReceivables$44KInventory−$64KPayables$85KPrepaid and other assets$92KOperating cash flow$20K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20261123363181
Q1 20261122059173
Q4 20251123063177
Q3 20251322873168
Q2 20251222075157
Q1 20251221479147
Q4 20241120779138
Q3 20241322592146

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026$20K−$7K—−$54K$43K$13K
Q1 2026$101K−$3K—−$53K−$31K$98K
Q4 2025−$354K−$9K—−$34K$103K−$363K
Q3 2025−$259K−$11K—−$20K$505K−$270K
Q2 2025$287K−$49K—−$60K−$74K$238K
Q1 2025−$81K−$40K—−$59K−$358K−$121K
Q4 2024−$164K−$18K−$4K−$38K$525K−$182K
Q3 2024−$122K—$34K−$30K−$502K−$122K

CV Sciences: income statement and cash flow

CV Sciences, Q2 2026: revenue $3.0M (-18% year over year), operating margin -10.1%. The chart follows the revenue to costs, profit and cash.

CV Sciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.